Navigation Links
Hitting target in cancer fight now easier with new nanoparticle platform, UCLA scientists say
Date:5/4/2011

The ability to use nanoparticles to deliver payloads of cancer-fighting drugs to tumors in the body could herald a fundamental change in chemotherapy treatment. But scientists are still at a relatively early stage in the implementation of this technology.

Although developing nanoparticles that work as "magic bullets" selectively targeting tumors while sparing normal, healthy tissues is still the goal, the reality is that most of these nanocarriers are removed through the liver and spleen before ever reaching their intended target. And many of the encapsulated drugs can be lost while the carriers circulate in the blood or degraded on the way to tumors.

In a study recently published in the journal ACS Nano, UCLA scientists report that by using engineered mesoporous silica nanoparticles (MSNPs) as delivery vehicles, they were able to achieve significant increases in the percentage of drug-carrying nanoparticles that reach and are retained at tumor sites.

The MSNP platform allows for the introduction of multiple and customized design features that can help optimize the delivery of chemotherapeutic drugs to a variety of cancer types, said the researchers, led by Dr. Andre Nel, a professor of medicine, pediatrics and public health and chief of the nanomedicine division in the UCLA Department of Medicine, and Jeffrey Zink, a professor in the UCLA Department of Chemistry and Biochemistry. Nel and Zink are also members of the California NanoSystems Institute at UCLA.

A key challenge in enhancing drug delivery has been improving nanocarriers' access to tumors by capitalizing on features like the leakiness of abnormal tumor blood vessels, which allows nanoparticles to slip through and be retained at tumor sites. To achieve that, particles must be designed to be the ideal size, to remain in the blood stream long enough by temporarily evading the liver and spleen, and to stably bind the drug.

The dynamic design features employed by the UCLA research team include the manipulation of the size and surface properties of the nanoparticle to improve tumor biodistribution and protected delivery. The study demonstrates how, through an iterative design process, the first-generation MSNP was redesigned and optimized to deliver doxorubicin to a cancer xenograft in a mouse model.

The team demonstrated a significant increase in particle retention at the tumor site: Approximately 10 to 12 percent of all the drug-loaded particles injected intravenously reached the tumor site. This high tumor distribution is exceptionally good, compared with other polymer- and copolymer-based nanodelivery platforms for which the best passive tumor targeting is in the range of 3.5 to 10 percent of injected particles, the researchers said.

The study also demonstrated efficient drug delivery and tumor cellkilling using the redesigned and optimized MSNP system in mice.

"The amount of doxorubicin being delivered to the tumor site was considerably higher than what could be achieved by the free drug, in addition to allowing efficient delivery into the cancer cells at the tumor site," said Nel, who is also a member of UCLA's Jonsson Comprehensive Cancer Center.

Moreover, the improved drug delivery was accompanied by a significant reduction in systemic side effects such as weight loss and reduced liver and renal injury.

"This is an important demonstration of how the optimal design of the MSNP platform can achieve better drug delivery in vivo," Nel said. "This delivery platform allows effective and protective packaging of hydrophobic and charged anticancer drugs for controlled and on-demand delivery. Not only are these design features superior to induce tumor shrinkage and apoptosis compared to the free drug, but they also dramatically improve the safety profile of systemic doxorubicin delivery."


'/>"/>

Contact: Jennifer Marcus
jmarcus@cnsi.ucla.edu
310-267-4839
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. Study shows hunger hitting closer to home
2. Chances of hurricane hitting Texas discussed at UH conference
3. How your body clock avoids hitting the snooze button
4. Why the swamp sparrow is hitting the high notes
5. MIT: Removable cloak for nanoparticles helps them target tumors
6. System in brain -- target of class of diabetes drugs -- linked to weight gain
7. La Jolla Institute identifies new therapeutic target for asthma, COPD and other lung disorders
8. Lesser-known Escherichia coli types targeted in food safety research
9. Target for lung cancer chemoprevention identified
10. Short rotation energy crops could help meet UKs renewable energy targets
11. Study identifies promising target for AIDS vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... ... ... Supplies of the critical medical isotope molybdenum-99 (Mo-99) are secure and reliable ... and Molecular Imaging (SNMMI) 2017 annual meeting in Denver, Colorado in June. Mo-99 ... million nuclear medicine procedures worldwide every year. (1) , Sally Schwarz, President of ...
(Date:6/27/2017)... ... June 27, 2017 , ... Brain State Technologies, a ... campaign on June 15th to fund production of the new B2v2 wearable brainwave ... Kickstarter goal by more than 150% in a little over a week. , ...
(Date:6/27/2017)... ... June 27, 2017 , ... Indiana-based Xylogenics ... yeast production and fermentation process. The efficiencies created by the newest strain ... most notably the ethanol industry wherein individual production plants are planning to invest ...
(Date:6/26/2017)... ... 2017 , ... Third Wave Bioactives, LLC announces the addition of Brett Thompson. ... business development and ensuring quality customer experience. , Brett brings to Third ... technical, marketing and sales roles. “Brett’s background working with customers and eye for market ...
Breaking Biology Technology: